Temporal analysis of clinico-pathological variables and biomarkers in cancer

However, these biomarkers are often dichotomised to facilitate easy analysis and interpretation. This categorisation removes a vast amount of information, particularly either side of the enforced boundaries, which otherwise could give improved insights into the prognosis of individuals.

This research focuses on using blood biomarkers measured at diagnosis, pre-treatment and post-treatment, in continuous form, to develop prognostic models in prostate (PCa) and oesophageal (OAC) cancers.